Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

876 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients.
Hoffmann JM, Schubert ML, Wang L, Hückelhoven A, Sellner L, Stock S, Schmitt A, Kleist C, Gern U, Loskog A, Wuchter P, Hofmann S, Ho AD, Müller-Tidow C, Dreger P, Schmitt M. Hoffmann JM, et al. Among authors: stock s. Front Immunol. 2018 Jan 10;8:1956. doi: 10.3389/fimmu.2017.01956. eCollection 2017. Front Immunol. 2018. PMID: 29375575 Free PMC article.
Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
Stock S, Übelhart R, Schubert ML, Fan F, He B, Hoffmann JM, Wang L, Wang S, Gong W, Neuber B, Hückelhoven-Krauss A, Gern U, Christ C, Hexel M, Schmitt A, Schmidt P, Krauss J, Jäger D, Müller-Tidow C, Dreger P, Schmitt M, Sellner L. Stock S, et al. Int J Cancer. 2019 Sep 1;145(5):1312-1324. doi: 10.1002/ijc.32201. Epub 2019 Feb 28. Int J Cancer. 2019. PMID: 30737788 Free article.
Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells.
Gong W, Hoffmann JM, Stock S, Wang L, Liu Y, Schubert ML, Neuber B, Hückelhoven-Krauss A, Gern U, Schmitt A, Müller-Tidow C, Shiku H, Schmitt M, Sellner L. Gong W, et al. Among authors: stock s. Cancer Immunol Immunother. 2019 Jul;68(7):1195-1209. doi: 10.1007/s00262-019-02354-4. Epub 2019 Jun 8. Cancer Immunol Immunother. 2019. PMID: 31177329 Free PMC article.
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.
Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, Penack O, Albanyan O, Stock S, Müller F, Karschnia P, Petrera A, Reid K, Faramand R, Davila ML, Modi K, Dean EA, Bachmeier C, von Bergwelt-Baildon M, Locke FL, Bethge W, Bullinger L, Mackensen A, Barba P, Jain MD, Subklewe M. Rejeski K, et al. Among authors: stock s. Sci Adv. 2023 Sep 22;9(38):eadg3919. doi: 10.1126/sciadv.adg3919. Epub 2023 Sep 22. Sci Adv. 2023. PMID: 37738350 Free PMC article.
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.
Märkl F, Benmebarek MR, Keyl J, Cadilha BL, Geiger M, Karches C, Obeck H, Schwerdtfeger M, Michaelides S, Briukhovetska D, Stock S, Jobst J, Müller PJ, Majed L, Seifert M, Klüver AK, Lorenzini T, Grünmeier R, Thomas M, Gottschlich A, Klaus R, Marr C, von Bergwelt-Baildon M, Rothenfusser S, Levesque MP, Heppt MV, Endres S, Klein C, Kobold S. Märkl F, et al. Among authors: stock s. J Immunother Cancer. 2023 May;11(5):e006436. doi: 10.1136/jitc-2022-006436. J Immunother Cancer. 2023. PMID: 37208128 Free PMC article.
876 results